| Item Type | Name |
|
Concept
|
Antigen Presentation
|
|
Concept
|
Receptors, Antigen, T-Cell, alpha-beta
|
|
Concept
|
Receptors, Antigen, T-Cell
|
|
Concept
|
B7-1 Antigen
|
|
Concept
|
Receptors, Antigen, T-Cell, gamma-delta
|
|
Academic Article
|
Thymus-leukemia antigen interacts with T cells and self-peptides.
|
|
Academic Article
|
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.
|
|
Academic Article
|
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
|
|
Academic Article
|
Expansion of natural (NK1+) T cells that express alpha beta T cell receptors in transporters associated with antigen presentation-1 null and thymus leukemia antigen positive mice.
|
|
Academic Article
|
An increased gamma delta T cell population in the intestine of thymus-leukemia antigen transgenic mice.
|
|
Academic Article
|
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
|
|
Academic Article
|
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide.
|
|
Academic Article
|
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
|
|
Academic Article
|
Cancer immunotherapy: in vivo imaging of adoptively transferred T cells in an immunocompetent host.
|
|
Academic Article
|
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity.
|
|
Academic Article
|
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
|
|
Academic Article
|
Transgenic mice expressing the thymus leukemia antigen fail to control cutaneous herpes simplex virus infection.
|
|
Academic Article
|
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
|
|
Academic Article
|
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
|
|
Academic Article
|
PD-L1 expression in triple-negative breast cancer.
|
|
Academic Article
|
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.
|
|
Academic Article
|
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
|
|
Academic Article
|
Cancer immunotherapy highlights from the 2014 ASCO Meeting.
|
|
Academic Article
|
The future of immune checkpoint therapy.
|
|
Academic Article
|
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Strategies for combining immunotherapy with radiation for anticancer therapy.
|
|
Academic Article
|
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
|
|
Academic Article
|
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy.
|
|
Academic Article
|
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
|
|
Academic Article
|
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
|
|
Academic Article
|
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
|
|
Academic Article
|
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
|
|
Academic Article
|
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
|
|
Academic Article
|
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
|
|
Academic Article
|
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
|
|
Academic Article
|
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
|
|
Academic Article
|
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
|
|
Academic Article
|
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
|
|
Academic Article
|
A potential biomarker for anti-PD-1 immunotherapy.
|
|
Academic Article
|
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.
|
|
Academic Article
|
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
|
|
Academic Article
|
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
|
|
Academic Article
|
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
|
|
Academic Article
|
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
|
|
Academic Article
|
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.
|
|
Academic Article
|
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
|
|
Concept
|
gp100 Melanoma Antigen
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
CTLA-4 Antigen
|
|
Academic Article
|
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
|
|
Academic Article
|
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.
|
|
Academic Article
|
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
|
|
Academic Article
|
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
|
|
Academic Article
|
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.
|
|
Academic Article
|
Dissecting the mechanisms of immune checkpoint therapy.
|
|
Academic Article
|
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
|
|
Academic Article
|
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
|
|
Academic Article
|
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ? Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
|
|
Academic Article
|
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
|
|
Academic Article
|
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
|
|
Academic Article
|
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
|
|
Academic Article
|
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Immune checkpoint therapy-current perspectives and future directions.
|
|
Academic Article
|
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
|
|
Academic Article
|
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
|